Clear cell papillary renal cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:12:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Clear cell papillary renal cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of JK06 for Patients with Advanced or Metastatic Cancer https://clinicaltrials.eu/trial/study-of-jk06-for-patients-with-advanced-or-metastatic-cancer/ Wed, 29 Apr 2026 15:01:44 +0000 https://clinicaltrials.eu/trial/study-of-jk06-for-patients-with-advanced-or-metastatic-cancer/ This clinical trial is focused on studying a new treatment for patients with unresectable locally advanced or metastatic cancer. The treatment being tested is called JK06, which is a type of medication known as an antibody-drug conjugate (ADC). This medication is given to patients through an infusion into a vein, which means it is delivered directly into the bloodstream. The study aims to understand how safe and tolerable this treatment is for patients, as well as to determine the best dose to use in future studies.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

]]> Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer https://clinicaltrials.eu/trial/study-of-jk08-pembrolizumab-and-lenvatinib-for-patients-with-advanced-or-metastatic-cancer/ Wed, 29 Apr 2026 14:29:43 +0000 https://clinicaltrials.eu/trial/study-of-jk08-pembrolizumab-and-lenvatinib-for-patients-with-advanced-or-metastatic-cancer/ This clinical trial is focused on studying a new treatment for patients with unresectable locally advanced or metastatic cancer. The treatment being tested is called JK08, which is an IL-15 antibody fusion protein that targets CTLA-4. This study will explore the use of JK08 both on its own and in combination with other treatments. The trial will also involve the use of Keytruda (known as pembrolizumab) and Lenvima (known as lenvatinib) in certain combinations. Keytruda is a medication used for various types of cancer, and Lenvima is a type of medication known as a receptor tyrosine kinase inhibitor, which helps to block certain proteins that promote cancer cell growth.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

]]> Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma https://clinicaltrials.eu/trial/study-comparing-savolitinib-and-durvalumab-with-sunitinib-and-durvalumab-for-patients-with-advanced-papillary-renal-cell-carcinoma/ Wed, 29 Apr 2026 14:28:17 +0000 https://clinicaltrials.eu/trial/study-comparing-savolitinib-and-durvalumab-with-sunitinib-and-durvalumab-for-patients-with-advanced-papillary-renal-cell-carcinoma/ This clinical trial is focused on studying a type of kidney cancer called papillary renal cell carcinoma (PRCC), which is driven by a specific factor known as MET. The study is looking at patients whose cancer cannot be removed by surgery and has spread to other parts of the body. The trial will test the effectiveness of a combination of two treatments, savolitinib and durvalumab, compared to another treatment called sunitinib and durvalumab given alone. Savolitinib is a medication that targets the MET factor, while durvalumab is an immunotherapy that helps the immune system fight cancer. Sunitinib is a medication that blocks certain proteins that help cancer cells grow.

The purpose of the study is to see how well these treatments work in stopping the cancer from getting worse. Participants will be randomly assigned to one of three groups: one group will receive savolitinib and durvalumab, another group will receive sunitinib, and the third group will receive durvalumab alone. The study will monitor the participants over time to see how long they live without the cancer getting worse and to check for any side effects from the treatments.

The trial will last for several years, and participants will have regular check-ups and tests to monitor their health and the progress of the cancer. The study aims to provide more information about the best treatment options for people with MET-driven PRCC, helping to improve future care for patients with this type of cancer.

]]>